The potential of GDNF as a treatment for Parkinson's disease

By Hurelbrink C.B.   Barker R.A.  

Experimental Neurology, Vol. 185, Iss. 1, 2004-01 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

GDNF treatment in Parkinson’s disease: time for controlled clinical trials?

By Brundin Patrik  

Brain, Vol. 125, Iss. 10, 2002-10 ,pp. : 2149-2151

Oxford University Press

Access to resources Recommend Favorite

Reactive Astrocytes of the Quinolinic Acid-Lesioned Rat Striatum Express GFR 1 as Well as GDNF in Vivo

By Bresjanac M.   Antauer G.  

Experimental Neurology, Vol. 164, Iss. 1, 2000-07 ,pp. : 53-59

Elsevier

Access to resources Recommend Favorite

Pharmacological Activities of Glial Cell Line-Derived Neurotrophic Factor (GDNF): Preclinical Development and Application to the Treatment of Parkinson's Disease

By Lapchak P.A.   Gash D.M.   Collins F.   Hilt D.   Miller P.J.   Araujo D.M.  

Experimental Neurology, Vol. 145, Iss. 2, 1997-06 ,pp. : 309-321

Elsevier

Access to resources Recommend Favorite

Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease

By  

Current Alzheimer Research, Vol. 8, Iss. 8, 2011-12 ,pp. : 853-859

Bentham Science Publishers

Access to resources Recommend Favorite